TABLE 1.
Mortality Hazard Ratio According to Different Cut-Points of MGMT Methylation Level During the First 9 Months After Diagnosis and After 9 Months
| MGMT Methylation level | N above/Nbelow | Patient OS During the First 9 Months After Diagnosis |
Patient OS From 9 Months After Diagnosis |
||
|---|---|---|---|---|---|
| HR | HR a (95% CI) | HR | HR a (95% CI) | ||
| Continuous | – | 1.00 | 1.00 (0.98, 1.02) | 0.97 | 0.97 (0.96, 0.98)*** |
| 2–100 versus 0–1 | 221/5 | 0.89 | 0.81 (0.11, 5.92) | 0.29 | 0.30 (0.11, 0.82)* |
| 5–100 versus 0–4 | 154/72 | 0.87 | 0.82 (0.44, 1.51) | 0.32 | 0.30 (0.21, 0.43)*** |
| 10–100 versus 0–9 | 117/109 | 1.00 | 0.96 (0.54, 1.73) | 0.36 | 0.36 (0.26, 0.49)*** |
| 15–100 versus 0–14 | 99/127 | 1.06 | 0.97 (0.54, 1.76) | 0.40 | 0.38 (0.27, 0.53)*** |
| 20–100 versus 0–19 | 79/147 | 1.31 | 1.18 (0.65, 2.15) | 0.41 | 0.38 (0.27, 0.55)*** |
| 25–100 versus 0–24 | 64/162 | 1.47 | 1.34 (0.73, 2.47) | 0.45 | 0.42 (0.28, 0.62)*** |
Abbreviations: Nabove, number of patients with MGMT methylation level above the cut-point; Nbelow, number of patients with MGMT methylation level below the cut-point; HR, mortality hazard ratio; CI, confidence interval; OS, overall survival.
a
Adjusted for age and performance status.
*
p < 0.05, ***p < 0.001.